Transplant News Network

A SERVICE OF CenterSpan home
[return to the TNN menu]

BioTransplant Continues MGH Collaboration; Acquires Eligix

CHARLESTOWN, Mass.—December 15, 2000· by TNN Medical Reporter Virginia Baskerville

BioTransplant Incorporated and Massachusetts General Hospital's Transplantation Biology Research Center have entered into a five-year agreement that renews their collaborative research in the transplantation of organs, tissues, and cells.

"The ultimate goals of the collaboration are to pioneer new approaches to prevent the need for long-term immunosuppressive treatment in the transplantation of human organs and enable functional tolerance of these transplanted tissues and organs," BioTransplant said in a statement.

Under the terms of the agreement, BioTransplant will continue to fund some of the research of Massachusetts General Hospital scientists, including David Sachs, Megan Sykes, and A. Benedict Cosimi. The hospital, in turn, has granted BioTransplant exclusive worldwide royalty-bearing rights to technology and inventions developed in the course of BioTransplant's funded research. See www.corporate-ir.net/ireye/ir_site.zhtml?ticker=btrn&script=410&layout=7&item_id=136240

* In other business, BioTransplant announced on December 11 that it has agreed to acquire Eligix Incorporated, a privately held biomedical device company. The transaction is expected to close in the first quarter of 2001. Products under development by Eligix include high-density microparticles with monoclonal antibodies on their surfaces, which can remove unwanted cells from blood and bone marrow, such as cells that cause graft-versus-host disease.
See www.corporate-ir.net/ireye/ir_site.zhtml?ticker=btrn&script=410&layout=7&item_id=137751

* At the recent annual meeting of the American Society for Hematology, BioTransplant and Massachusetts General Hospital reported the results of a number of studies dealing with the use of nonmyeloablative conditioning in preparation for bone marrow transplantation in patients with advanced refractory blood cancers.
See http://biz.yahoo.com/prnews/001205/ca_biotran.html and www.corporate-ir.net/ireye/ir_site.zhtml?ticker=btrn&script=410&layout=7&item_id=136440


Feedback:

 Help
Colleague's e-mail
Colleague's name
Your name

CenterSpan home
Copyright © 2000 CenterSpan
This site developed and maintained by SLACK Incorporated
Questions or comments? E-mail the Webmaster

Please be aware that medical advice, diagnoses and physician references cannot be obtained from this site.